Our findings contribute to evidence of the potential clinical utility of mucin-1 as a prognostic biomarker for IPF, particularly in identifying a susceptible subgroup for whom close monitoring for adverse outcomes and pulmonary function deterioration is critical, despite ongoing antifibrotic therapy. The gene discussed is MUC1; the disease is idiopathic pulmonary fibrosis.